In this program, the decision is not whether a technology should be funded in general, but whether it is justified to try here and now for this person. That is a fundamentally different ethical architecture from the HTA institutional frameworks we have. …
The two sides of decision-making - compassion and calculation in funding outcomes
February 22, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech -
Medicines Australia appoints former AbbVie executive to key leadership role
August 13, 2026 - - Latest News -
VVMF and Optosleep partner to advance Australian gene therapy for sleep apnoea
August 13, 2026 - - Latest News -
Survey exposes deep gaps in neurological care across Australia
August 13, 2026 - - Latest News -
Australia 'is not an island' on pricing and we cannot be so arrogant to expect free product
August 13, 2026 - - Latest News